Assessing the burden of Taenia solium cysticercosis in Burundi, 2020.
Burden
Burundi
Cysticercosis
Economic impact
Epidemiology
Epilepsy
Neurocysticercosis
Pig
Taenia solium
zDALY
Journal
BMC infectious diseases
ISSN: 1471-2334
Titre abrégé: BMC Infect Dis
Pays: England
ID NLM: 100968551
Informations de publication
Date de publication:
14 Nov 2022
14 Nov 2022
Historique:
received:
05
05
2022
accepted:
07
11
2022
entrez:
15
11
2022
pubmed:
16
11
2022
medline:
18
11
2022
Statut:
epublish
Résumé
Taenia solium cysticercosis is a zoonotic disease that is endemic in many low- and middle-income countries where risk factors for disease transmission are present. The economic impact of cysticercosis on public health and on the pig production sector is not well known in many of those countries, including Burundi. This study aimed at estimating the burden of T. solium cysticercosis in Burundi including data on humans and pigs. Epidemiological and economic data were collected from literature up to July 30, 2021 and governmental and non-governmental agencies. Direct and indirect costs for neurocysticercosis (NCC)-associated epilepsy and losses due to porcine cysticercosis were estimated to assess the economic burden, while the health burden was estimated using zoonotic disability-adjusted life years (zDALYs). Different probability distributions (Uniform, Beta, Dirichlet and Gamma) were applied depending on the type of epidemiological parameter. Monte Carlo simulations and 100,000 iterations were used to calculate the 95% uncertainty interval (UI) for each parameter and perform sensitivity analyses. In Burundi, 4.26 million USD (95% UI, 1,858,308-8,190,951) were estimated as economic impact due to T. solium cysticercosis in humans and pigs, of which 40.2% (95% UI, 10.3-75.1) of the total costs were due to NCC-associated epilepsy and 59.8% (95% UI, 24.9-89.7) of the losses due to porcine cysticercosis. The cost per NCC-associated epilepsy case was 72 USD (95% UI, 25-168), representing 30.8% of the GDP per capita in 2020. The probable incident cases and deaths for NCC-associated epilepsy were 9065 (95% UI, 2370-16,716) and 61 (95% UI, 16-114), respectively. More than 2 zDALYs (95% UI, 1.1-3.4) per thousand person-years was estimated, of which an average of 1.3 DALYs [0;0] (95% UI, 0.3-2.6) was due to NCC- associated epilepsy and 0.8 animal loss equivalents (ALEs) (95% UI, 0.3-1.5) due to porcine cysticercosis. This study provides evidence of a significant burden of T. solium cysticercosis for Burundi's population. We urge policy makers to use these evidence-based results and put T. solium cysticercosis on the public health agenda of the country. This study recommends urgent action to find solutions for integrated control strategies for T. solium cysticercosis in Burundi.
Sections du résumé
BACKGROUND
BACKGROUND
Taenia solium cysticercosis is a zoonotic disease that is endemic in many low- and middle-income countries where risk factors for disease transmission are present. The economic impact of cysticercosis on public health and on the pig production sector is not well known in many of those countries, including Burundi. This study aimed at estimating the burden of T. solium cysticercosis in Burundi including data on humans and pigs.
METHODS
METHODS
Epidemiological and economic data were collected from literature up to July 30, 2021 and governmental and non-governmental agencies. Direct and indirect costs for neurocysticercosis (NCC)-associated epilepsy and losses due to porcine cysticercosis were estimated to assess the economic burden, while the health burden was estimated using zoonotic disability-adjusted life years (zDALYs). Different probability distributions (Uniform, Beta, Dirichlet and Gamma) were applied depending on the type of epidemiological parameter. Monte Carlo simulations and 100,000 iterations were used to calculate the 95% uncertainty interval (UI) for each parameter and perform sensitivity analyses.
RESULTS
RESULTS
In Burundi, 4.26 million USD (95% UI, 1,858,308-8,190,951) were estimated as economic impact due to T. solium cysticercosis in humans and pigs, of which 40.2% (95% UI, 10.3-75.1) of the total costs were due to NCC-associated epilepsy and 59.8% (95% UI, 24.9-89.7) of the losses due to porcine cysticercosis. The cost per NCC-associated epilepsy case was 72 USD (95% UI, 25-168), representing 30.8% of the GDP per capita in 2020. The probable incident cases and deaths for NCC-associated epilepsy were 9065 (95% UI, 2370-16,716) and 61 (95% UI, 16-114), respectively. More than 2 zDALYs (95% UI, 1.1-3.4) per thousand person-years was estimated, of which an average of 1.3 DALYs [0;0] (95% UI, 0.3-2.6) was due to NCC- associated epilepsy and 0.8 animal loss equivalents (ALEs) (95% UI, 0.3-1.5) due to porcine cysticercosis.
CONCLUSIONS
CONCLUSIONS
This study provides evidence of a significant burden of T. solium cysticercosis for Burundi's population. We urge policy makers to use these evidence-based results and put T. solium cysticercosis on the public health agenda of the country. This study recommends urgent action to find solutions for integrated control strategies for T. solium cysticercosis in Burundi.
Identifiants
pubmed: 36376817
doi: 10.1186/s12879-022-07849-7
pii: 10.1186/s12879-022-07849-7
pmc: PMC9661784
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
851Informations de copyright
© 2022. The Author(s).
Références
Trans R Soc Trop Med Hyg. 1998 Jul-Aug;92(4):411-4
pubmed: 9850394
Epilepsia. 2004 Jun;45(6):673-7
pubmed: 15144433
Epilepsia. 2003 Jul;44(7):950-5
pubmed: 12823579
Bull Soc Pathol Exot. 1990;83(2):288-9
pubmed: 2208460
PLoS Med. 2015 Dec 03;12(12):e1001920
pubmed: 26633705
Neurophysiol Clin. 2005 Feb;35(1):1-10
pubmed: 15808962
Vet Parasitol Reg Stud Reports. 2021 Jan;23:100514
pubmed: 33678369
Vet Parasitol. 2016 Apr 15;220:67-71
pubmed: 26995723
One Health. 2017 Nov 28;5:40-45
pubmed: 29911164
Acta Trop. 2003 Jun;87(1):35-42
pubmed: 12781376
J Helminthol. 2015 Sep;89(5):559-64
pubmed: 24865274
PLoS Negl Trop Dis. 2009;3(3):e406
pubmed: 19333365
PLoS Negl Trop Dis. 2012;6(2):e1521
pubmed: 22363827
Lancet. 2012 Dec 15;380(9859):2129-43
pubmed: 23245605
PLoS Negl Trop Dis. 2015 Jul 06;9(7):e0003919
pubmed: 26147942
Int J Public Health. 2014 Jun;59(3):571-4
pubmed: 24748107
Acta Trop. 2017 Jan;165:161-169
pubmed: 26802489
Lancet Glob Health. 2015 Nov;3(11):e712-23
pubmed: 26475018
PLoS Med. 2009 Jul 21;6(7):e1000097
pubmed: 19621072
PLoS Negl Trop Dis. 2020 Jul 31;14(7):e0008410
pubmed: 32735585
Trans R Soc Trop Med Hyg. 1997 Jul-Aug;91(4):389-91
pubmed: 9373628
Acta Trop. 2017 Jan;165:141-154
pubmed: 26756713
Bull Soc Pathol Exot. 1992;85(5):374-7
pubmed: 1292797
Trans R Soc Trop Med Hyg. 1997 Sep-Oct;91(5):525-7
pubmed: 9463656
Acta Trop. 2003 Jun;87(1):79-86
pubmed: 12781381
PLoS Negl Trop Dis. 2011 May;5(5):e1152
pubmed: 21629722
Lancet Neurol. 2019 Apr;18(4):357-375
pubmed: 30773428
BMC Infect Dis. 2018 Mar 13;18(1):127
pubmed: 29534702
PLoS Negl Trop Dis. 2014 Jan 02;8(1):e2634
pubmed: 24392178
Int J Public Health. 2014 Jun;59(3):565-9
pubmed: 24752429
Lancet Neurol. 2005 Jan;4(1):21-31
pubmed: 15620854
Trop Med Int Health. 2006 Jun;11(6):906-16
pubmed: 16772013
Trop Med Int Health. 2007 Jul;12(7):895-901
pubmed: 17596257
Clin Microbiol Rev. 2020 May 27;33(3):
pubmed: 32461308
Epilepsia. 2007 May;48(5):894-9
pubmed: 17508999
Brain Res Bull. 2019 Feb;145:30-38
pubmed: 30170188
PLoS Negl Trop Dis. 2010 Nov 02;4(11):e870
pubmed: 21072231
PLoS Negl Trop Dis. 2020 Jun 8;14(6):e0008384
pubmed: 32511228
J Ethnopharmacol. 2015 Sep 15;173:338-51
pubmed: 26232628
Rev Sci Tech. 2017 Apr;36(1):147-161
pubmed: 28926019
Lancet Neurol. 2014 Oct;13(10):1029-44
pubmed: 25231525
Lancet. 2003 Aug 16;362(9383):547-56
pubmed: 12932389